Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1605496 | 0.88 | EPHX2 (0.37) | P2RX7CNR2CNR1EPHX2HPGD | |
| SCHEMBL6504532 | 0.80 | SMN1; SMN2 (0.38) | P2RX7EPHX2 | |
| SCHEMBL6499906 | 0.79 | P2RX7 (0.52) | P2RX7CNR2HPGD | |
| SCHEMBL6506039 | 0.77 | MAPT (0.36) | CNR2CNR1EPHX2 | |
| SCHEMBL6503448 | 0.77 | SMN1; SMN2 (0.42) | P2RX7HPGD | |
| Bromide SCHEMBL6508115 | 0.75 | GLA (0.36) | HPGD | |
| SCHEMBL6500205 | 0.75 | DPP9 (0.46) | CNR2 | |
| SCHEMBL6388648 | 0.74 | P2RX7 (0.50) | P2RX7HPGD | |
| SCHEMBL6427832 | 0.74 | ALDH1A1 (0.33) | — | |
| SCHEMBL6427826 | 0.72 | KMT2A (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | P2RX7 3883/4885CNR2 1096/4885CNR1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.